To our knowledge, this is the first study that has evaluated the synergy of treatment efficacy of HER2-targeted therapy and radiation treatment in vivo, quantified changes in the sequencing of the combination treatment of trastuzumab plus fractionated radiation in vitro, and utilized molecular imaging to evaluate longitudinal alterations in the tumor microenvironment. This evidence concerns the gene ERBB2 and neoplasm.